+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID03161223

Phase 12a Study of Durvalumab Combined With Pralatrexate, Romidepsin, and Oral 5-Azacitidine for Treating Relapsed or Refractory Peripheral T-Cell Lymphoma

Led by University of Virginia · Updated on 2022-03-31

148

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying combinations of the drug durvalumab with pralatrexate, romidepsin, and oral 5-azacitidine to treat patients with peripheral T-cell lymphoma PTCL, a rare and aggressive type of non-Hodgkins lymphoma. The study is designed as an open-label Phase 12a trial, with an initial phase 1 dose-finding portion followed by a phase 2 portion for the most promising treatments. The goal is to find the highest safe dose and evaluate safety and effectiveness signals for these drug combinations.

CONDITIONS

Brief Title

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

Research Team

A

Abdelmalek Marian

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here